Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy
AkebiaCares offers services that include assisting patients and health care providers through the benefits investigation process, prior authorizations, appeals, copay assistance, and a patient assistance program for financially eligible patients. Patients can access these programs at www.akebiacares.com
“Programs like AkebiaCares can provide significant help to patients who
need assistance navigating their health insurance benefits and affording
out-of-pocket costs. We applaud Akebia’s commitment to helping people
with CKD live healthier lives,” said
“Akebia is committed to advancing care for patients with CKD and helping
them better manage their disease,” stated
About Akebia Therapeutics
About Auryxia® (ferric citrate) Tablets
Auryxia (ferric citrate) was approved by the FDA on
IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA® (ferric
AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis.
WARNINGS AND PRECAUTIONS
- Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy.
- Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children.
Most common adverse reactions with AURYXIA were:
- Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%).
- Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%).
- Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman.
To report suspected adverse reactions, contact Akebia
Therapeutics at 1-844-445-3799.
Please see full Prescribing Information
Kristen K. Sheppard, Esq.